These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 21151616)

  • 1. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
    Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
    Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CaMKII exacerbates heart failure progression by activating class I HDACs.
    Zhang M; Yang X; Zimmerman RJ; Wang Q; Ross MA; Granger JM; Luczak ED; Bedja D; Jiang H; Feng N
    J Mol Cell Cardiol; 2020 Dec; 149():73-81. PubMed ID: 32971072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure: the pivotal role of histone deacetylases.
    Hewitson R; Dargan J; Collis D; Green A; Moorjani N; Ohri S; Townsend PA
    Int J Biochem Cell Biol; 2013 Feb; 45(2):448-53. PubMed ID: 23178536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors.
    Han Y; Nie J; Wang DW; Ni L
    Front Cardiovasc Med; 2022; 9():931475. PubMed ID: 35958418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
    Kee HJ; Eom GH; Joung H; Shin S; Kim JR; Cho YK; Choe N; Sim BW; Jo D; Jeong MH; Kim KK; Seo JS; Kook H
    Circ Res; 2008 Nov; 103(11):1259-69. PubMed ID: 18849323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy.
    Oka S; Ago T; Kitazono T; Zablocki D; Sadoshima J
    J Mol Med (Berl); 2009 Aug; 87(8):785-91. PubMed ID: 19424677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
    Raghunathan S; Goyal RK; Patel BM
    Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-sirtuin histone deacetylases in the control of cardiac aging.
    Ferguson BS; McKinsey TA
    J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
    Eom GH; Kook H
    BMB Rep; 2015 Mar; 48(3):131-8. PubMed ID: 25388210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
    Ren L; Wu XS; Li YQ
    Yi Chuan; 2020 Jun; 42(6):536-547. PubMed ID: 32694112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
    Wang Z; Zhao YT; Zhao TC
    Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2.
    Jayathilaka N; Han A; Gaffney KJ; Dey R; Jarusiewicz JA; Noridomi K; Philips MA; Lei X; He J; Ye J; Gao T; Petasis NA; Chen L
    Nucleic Acids Res; 2012 Jul; 40(12):5378-88. PubMed ID: 22396528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
    Trivedi CM; Luo Y; Yin Z; Zhang M; Zhu W; Wang T; Floss T; Goettlicher M; Noppinger PR; Wurst W; Ferrari VA; Abrams CS; Gruber PJ; Epstein JA
    Nat Med; 2007 Mar; 13(3):324-31. PubMed ID: 17322895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.
    Zhang CL; McKinsey TA; Chang S; Antos CL; Hill JA; Olson EN
    Cell; 2002 Aug; 110(4):479-88. PubMed ID: 12202037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.
    Weeks KL; Avkiran M
    J Physiol; 2015 Apr; 593(8):1785-97. PubMed ID: 25362149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone deacetylases for heart failure.
    Bush EW; McKinsey TA
    Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
    Evans LW; Bender A; Burnett L; Godoy L; Shen Y; Staten D; Zhou T; Angermann JE; Ferguson BS
    J Nutr Biochem; 2020 May; 79():108339. PubMed ID: 32007664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.